



HAL
open science

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study

Jerome Dumortier, V. Leroy, C. Duvoux, V. De Lédighen, C. Francoz, P. Housel-Debry, S. Radenne, L. d'Alteroche, C. Fougerou-Leurent, V. Canva, et al.

► To cite this version:

Jerome Dumortier, V. Leroy, C. Duvoux, V. De Lédighen, C. Francoz, et al.. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study. *Liver Transplantation*, 2016, 22 (10), pp.1367–1378. 10.1002/lt.24505 . hal-01397762

HAL Id: hal-01397762

<https://univ-rennes.hal.science/hal-01397762>

Submitted on 4 Jan 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation: results from the CO23 ANRS CUPILT study

Short Title: Treatment of post-transplant HCV recurrence with severe fibrosis

Jérôme DUMORTIER¹, Vincent LEROY², Christophe DUVOUX³, Victor de LEDINGHEN⁴, Claire FRANCOZ⁵, Pauline HOUSSEL-DEBRY⁶, Sylvie RADENNE⁷, Louis d'ALTEROCHE⁸, Claire FOUGEROU-LEURENT⁹, Valérie CANVA¹⁰, Vincent di MARTINO¹¹, Filomena CONTI¹², Nassim KAMAR¹³, Christophe MORENO¹⁴, Pascal LEBRAY¹², Albert TRAN¹⁵, Camille BESCH¹⁶, Alpha DIALLO¹⁷, Alexandra ROHEL¹⁷, Emilie ROSSIGNOL⁹, Armand ABERGEL¹⁸, Danielle BOTTA-FRIDLUND¹⁹, Audrey COILLY²⁰, Didier SAMUEL²⁰, Jean-Charles DUCLOS-VALLEE²⁰, Georges-Philippe PAGEAUX²¹

¹ Hospices Civils de Lyon, Hôpital Edouard Herriot, and Université Claude Bernard Lyon 1, Lyon, France ;

² CHU de Grenoble, Pôle Digidune, Clinique Universitaire d'Hépatogastroentérologie, and INSERM / Université Grenoble Alpes U823, IAPC Institut Albert Bonniot, Grenoble, France;

³ AP-HP, Hôpital Henri Mondor, Service d'Hépatologie, Créteil, France ;

⁴ CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépatologie, and INSERM U1053, Université Bordeaux, Bordeaux, France ;

⁵ AP-HP, Hôpital Beaujon, Service d'Hépatologie, and Université Paris Diderot et INSERM U1149, Centre de Recherche sur l'Inflammation, Clichy, France ;

⁶ CHU de Rennes, ¹⁷Service des Maladies du Foie, Rennes, France;

⁷ Hospices Civils de Lyon, Hôpital de la Croix Rousse, Service d'Hépatologie, Lyon,, France;

⁸ CHU Trousseau, Service d'hépatogastroentérologie, Tours, France;

⁹ CHU de Rennes, Unité de Pharmacologie clinique, and Centre d'Investigation clinique INSERM 1414, Rennes, France;

¹⁰ CHU de Lille, Hôpital Claude Huriez, Services Maladies de l'Appareil Digestif, Lille, France;

¹¹ CHU de Besançon, Hôpital Jean Minjot, Service d'Hépatologie, and Université de Franche Comté, Besançon, France;

¹² AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service d'hépatogastroentérologie, and Université Pierre et Marie Curie Paris 6, INSERM UMR-S938, Paris, France;

¹³ CHU Rangueil, Département de néphrologie et de transplantation d'organes, and Université de Toulouse, Toulouse, France;

¹⁴ CUB Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgique;

¹⁵ CHU de Nice, Hôpital de l'Archet 2, Service d'hépatologie, and INSERM U1065, and Université de Nice-Sophia-Antipolis, Nice, France;

¹⁶ CHU de Strasbourg, Service de transplantation, Strasbourg, France ;

¹⁷ Unit for Basic and Clinical research on viral hepatitis, ANRS (France REcherche Nord&Sud Sida-hiv Hépatites) Paris, France;

¹⁸ CHU Estaing, Service d'hépto-gastroentérologie, and Université d'Auvergne, UMR CNRS 6284, Clermont-Ferrand, France;

¹⁹ AP-HM, Hôpital de la Conception, Service d'hépto-gastroentérologie, Marseille, France;

²⁰ AP-HP, Hôpital Paul Brousse, Centre Hépto-Biliaire, and Université Paris-Sud, and Université Paris-Saclay, UMR-S 1193, and INSERM Unité 1193, and DHU Hepatinov, Villejuif, France;

²¹ CHU Saint-Eloi, Département d'hépto-gastroentérologie et de transplantation hépatique, and Université de Montpellier, Montpellier, France;

Abbreviations

ANRS: France REcherche Nord&Sud Sida-hiv Hépatites CUPILT: Compassionate use of protease inhibitors in viral C liver transplantation

BOC: Boceprevir

DAA: Direct-acting antivirals

DCV: Daclatasvir

EOT: End-of-treatment

HCC: Hepatocellular carcinoma

HCV: Hepatitis C virus

HIV: Human immunodeficiency virus

IQR: Interquartile range

LT: Liver Transplantation

LDV: Ledipasvir

MDRD: Modified Diet in Renal Disease

MELD: Model for end-stage liver disease

PEG: Pegylated alpha interferon

RBV: Ribavirin

SAE: Serious adverse event

SMV: Simeprevir

SOF: Sofosbuvir

SVR: Sustained virological response

TLV: Telaprevir

Correspondence:

Pr Jérôme Dumortier

Service d'Hépatogastroentérologie, hôpital Edouard Herriot, CHU de Lyon, France.

Tel: +33 472110111

Fax: +33 472110147

E-mail: jerome.dumortier@chu-lyon.fr

Disclosures:

- Jérôme Dumortier has been a clinical investigator, speaker and/or consultant for Astellas, Gilead Sciences, Janssen Pharmaceuticals, Novartis and Roche.
- Vincent Leroy has been a clinical investigator, speaker and/or consultant for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Roche.
- Georges-Philippe Pageaux has been a clinical investigator, speaker and/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Novartis.

- Jean-Charles Duclos-Vallée has been a clinical investigator, speaker and/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Abbvie, Novartis and Roche.
- Audrey Coilly has been a clinical investigator, speaker and/or consultant for Abbvie, Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Novartis.

Clinical Trial Identifier: NCT01944527

Grant support: The study was sponsored and funded by The National Agency for Research on AIDS and Viral Hepatitis (ANRS).

Title character count: 147

Abstract word count: 240

Overall manuscript word count: 3653

Author Contributions:

Jérôme Dumortier, Vincent Leroy, Audrey Coilly, Georges-Philippe Pageaux and Jean-Charles Duclos-Vallée contributed to the conception and design of this study and to the preparation and finalization of the manuscript. Jérôme Dumortier, Vincent Leroy, Christophe Duvoux, Victor de Ledinghen, Claire Francoz, Pauline Houssel-Debry, Sylvie Radenne, Louis d'Alteroche, Valérie Canva, Vincent di Martino, Filomena Conti, Nassim Kamar, Christophe Moreno, Pascal Lebray, Albert Tran, Camille Besch, Armand Abergel, Danielle Botta-Fridlund, Audrey Coilly, Georges-Philippe Pageaux, Jean-Charles Duclos-Vallée and Didier Samuel recruited patients into the study and participated in data collection and data analysis. Claire Fougerou-Leurent, Alpha Diallo, Alexandra Rohel, Emilie Rossignol, contributed to data analysis. All authors critically reviewed the article for important intellectual content and approved the final draft for submission.

ABSTRACT

Recurrence of HCV after liver transplantation (LT) can rapidly lead to liver graft cirrhosis, and therefore graft failure and re-transplantation or death. The aim of the present study was to assess efficacy and tolerance of sofosbuvir (SOF)-based regimens for the treatment of HCV recurrence in patients with severe fibrosis after LT. The CUPILT study is a prospective multicenter cohort including patients with HCV-recurrence following LT treated with second generation direct antivirals. The present study focused on patients included between Oct 2013 and Nov 2014 and diagnosed with HCV recurrence and liver graft extensive fibrosis (METAVIR F3/F4). A SOF-based regimen was administered to 125 patients fulfilling inclusion criteria. The median delay from LT was 95.9 ± 69.6 months. The characteristics of patients were: mean age: 59.4 ± 9.0 years; male: 78.4%, infected by HCV G1: 78.2%, mean HCV RNA: 6.1 ± 1.0 log IU/ml. Eighty patients had failed previous post-LT antiviral therapy (64.0%) including triple therapy with first generation protease inhibitors in 19 (15.2%) cases. The main combination regimen was SOF/daclatasvir (73.6%). Ribavirin was used in 60 patients. Sustained virological response 12 weeks after treatment was 92.8% (on an intent-to-treat basis); seven cases of virological failure were observed. Serious adverse-events occurred in 25.6% of the patients during antiviral treatment. During antiviral treatment and follow-up, 3 patients were re-transplanted and 4 patients died. In conclusion, SOF-based antiviral treatment shows very promising results in patients with HCV recurrence and severe fibrosis after LT.

Key-words: liver transplantation, hepatitis C virus, fibrosis, cirrhosis, treatment, sofosbuvir

Introduction

Liver disease related to hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), is the main indication for liver transplantation (LT) (1, 2). In patients transplanted with detectable HCV RNA, HCV infection of the graft is an almost universal phenomenon responsible for an increased risk of mortality and graft loss (3). Chronic liver disease caused by HCV infection progresses more rapidly in immunosuppressed individuals than in immunocompetent individuals, leading to cirrhosis in up to 20-30% of patients, five years after LT (4, 5). The use of second-generation direct acting antivirals (DAAs) could be a major advance in these difficult-to-treat patients because of their antiviral potency and their usual good tolerance, especially when used as interferon-free combinations. Sofosbuvir (SOF) is a potent inhibitor of the HCV NS5b polymerase that has a pangenotypic activity and a high genetic barrier to resistance, and has been available in France since October 2013, initially in the frame of the French early access program. The ANRS C023 “Compassionate use of Protease Inhibitors in viral C Liver Transplantation” (CUPILT) study is a prospective multicenter cohort study sponsored and funded by ANRS (France REcherche Nord&Sud Sida-hiv Hépatites) that has enrolled liver transplant recipients with HCV-recurrence treated with second generation DAAs. The aim of the present study was to describe the virological, biochemical and clinical outcome of patients included in the CUPILT cohort, presenting with severe recurrence of hepatitis C according to METAVIR fibrosis stage (F3 or F4) and treated with SOF-based therapy.

Patients and methods

Patients

The ANRS CO23-CUPILT study is conducted in 25 French and Belgium LT centers (ClinicalTrials.gov number NCT01944527). To be included in the cohort, patients had to be transplanted for HCV-related liver complication, presented with allograft HCV recurrence, and treated with second generation DAA. The main criteria for exclusion were age less than 18 years and pregnancy. From October 2013 to December 2015, 699 patients with HCV recurrence have been included in the cohort.

Study design

The present study focuses on patients included in the CUIPILT study presenting hepatitis C recurrence with severe fibrosis, who were followed at least 12 weeks after the end of their antiviral treatment. The assessment of severe fibrosis (METAVIR F3/F4) was established according to histological analysis of a liver biopsy and/or the result of transient elastography (Fibroscan[®]). For the latter, patients who had liver stiffness ranging from 9.6 kPa to 14.4 kPa were considered to have F3 METAVIR stage and patients who had values equal or above 14.5 kPa were considered F4 (6).

SOF, daclatasvir (DCV), simeprevir (SMV) and ledipasvir (LDV) (in fixed combination with SOF for the last three) have been successively available throughout the inclusion period. Treatment regimens were at the discretion of investigators. RBV use and dosing were at investigator's discretion according to weight and renal function. Planned duration of treatment was 12 or 24 weeks. However, investigators were allowed to extend treatment duration according to their clinical judgment in case of sub-optimal response. Modifications in the dose of calcineurin and mTOR inhibitors were performed at investigator's discretion on the basis of trough levels of tacrolimus, cyclosporine, sirolimus and everolimus.

The patients were not randomized, thus the study did not allow comparisons between the treatment regimens.

The protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the "Sud Méditerranée I" Ethics Committee (France). Written informed consent was obtained from each patient before enrolment.

Study assessments

Clinical evaluation including clinical signs of decompensated liver disease (ascites, hepatic encephalopathy) and laboratory tests were performed at baseline and at scheduled visits throughout treatment and follow-up periods (weeks 2, 4, 8, 12, 16, 20, 24, 36). HCV RNA level was measured with a real-time PCR-based assay, either COBAS AmpliPrep[®] or COBAS TaqMan[®] (Roche Molecular Systems, Pleasanton, California) with a lower limit of quantification of 15 IU/mL or m2000_{SP}/m2000_{RT} (Abbott Molecular, Des Plaines, Illinois), with a lower limit of quantification of 12 IU/mL.

End-points

Study primary end point was the sustained virological response (SVR) defined as undetectable HCV RNA during and 12 weeks after treatment discontinuation (SVR12). Secondary end points included laboratory liver tests, evaluation of drug-drug interactions with immunosuppressive drugs and evaluation of safety over the full duration of treatment.

Safety

The following adverse events were collected if they occurred after initiation of therapy and up to 48 weeks after the end of treatment (follow-up): serious adverse event (SAE), defined in the Table 6, clinical and laboratory grade 3 or 4 adverse events (assessed with the Inserm-ANRS scale for grading of adverse events seriousness v6 of September 9th 2003 given in Appendix Y) and any grade of adverse events related to neutrophils, platelets, prothrombin, bilirubin, creatinin, haemoglobin or infections. The management of anemia (RBV dose reductions and/or erythropoietin administration, authorized in France when the hemoglobin level is below 10 g/dL, and/or blood transfusion) was at the investigator's discretion.

Statistical analysis

Statistical analyses were performed with an intent-to-treat basis using SAS statistical software (SAS Institute, Cary, NC, USA). Continuous variables were expressed by mean and standard deviation and categorical variables were expressed by the number of patients and percentages. Differences in baseline characteristics between groups were evaluated using one-way analysis of variance for continuous data and the chi-square test or Fisher's exact test for categorical data. A paired t-test was used to test for change over time in continuous variable.

Accepted Article

Results

Study population

The study population consisted in 125 patients included between Oct 2013 and Nov 2014: 75 patients with METAVIR F4 HCV recurrence and 50 patients with METAVIR F3 HCV recurrence. The main characteristics of patients are presented in Table 1. The majority of patients was male (78.4%), infected by HCV genotype 1 (78.2%), had failed previous post-LT antiviral therapy (63.7%) including triple therapy with first generation protease inhibitors in 19 (15.2%) patients and SOF/RBV combination in 2 patients. Resistance testing before starting antiviral treatment was not systematically performed. This has been added. Four patients (3.2%) were co-infected with HIV. Immunosuppression was based on cyclosporine (30.4%) or tacrolimus (56.0%), and mycophenolate mofetil in 56.8% of cases. The mean time between LT and treatment initiation was 95.9 ± 69.6 months. Among the 73 cirrhotic patients with available data, 14 (19.2%) had ascites.

The following antiviral regimens were used (Table 2): SOF/RBV, SOF/PEG/RBV, SOF/DCV±RBV, SOF/LDV/RBV, SOF/SMV. RBV was used in 60 patients (48.0%). Daily dosages were as follows: 200 mg (n=2 (3.4%)), 400 mg (n=10 (16.9%)), 600 mg (n=18 (30.5%)), 800 mg (n=13 (22.0%)), 1000 mg (n=10 (16.9%)), 1200 mg (n=6 (10.2%)). Planned duration of treatment was 12 (14.4%) or 24 weeks (85.6%). Eventually, 2 patients received 28 weeks of treatment, 4 patients received 32 weeks, 3 patients received 36 weeks and 1 patient received 48 weeks of treatment. This was done because of slow virological response. Treatment regimens were SOF+DCV (n=7), SOF+DCV+RBV (n=1), SOF+RBV (n=1) and SOF+SMV/SOF+DCV (n=1).

Virological response

Table 3 summaries the rates of virological response. A rapid HCV RNA decline was observed in all patients after initiation of treatment. As shown in Figure 1, viral kinetics were similar between F3 and F4 groups. All but one patient had undetectable HCV RNA at end of treatment (EOT). In addition, 6 patients experienced relapse: at follow-up week 4 in 5 patients and at follow-up week 12 in one patient in whom

follow-up week 4 time point was missing. Characteristics of the 7 patients who presented virological failure are summarized in Table 4. On an intention-to-treat basis analysis, global SVR12 rate was 92.8%. It was 68.4% in patients who received a SOF/RBV combination (n=19), 100.0% in patients who received the SOF/PEG/RBV (n=5) and 97.0% in patients who received a combination of 2 DAA (n=101). Figure 2 describes the SVR12 rates according to treatment regimen, genotype, duration of treatment and previous HCV therapy post-LT.

Evolution of liver function tests

A rapid decrease of ALT, AST, and γ GT serum levels was observed after treatment initiation (Table 5). At the end of antiviral treatment and according to the stage of fibrosis, the rate of patients with normal values was 91.8% and 84.1% for ALT, 89.8% and 73.9% for AST, and 63.3% and 41.8% for γ GT, for F3 or F4 groups, respectively.

Clinical and liver function outcome

Evolution of biological liver function parameters is described in Table 5. BMI, albumin level and platelet count significantly improved, INR and bilirubin level did not change and creatinine and GFR significantly worsened. In summary, between D0 and EOT, in the group of 75 cirrhotic patients, Child score (when available, n=47) improved in 21 cases (44.7%) and worsened in 5 cases (10.6%) and MELD score (when available, n=64) improved in 25 cases (39.1%) and worsened in 26 cases (40.6%). In addition, between D0 and follow-up week 12, in the group of 75 cirrhotic patients, Child score (when available, n=45) improved in 20 cases (44.4%) and worsened in 5 cases (11.1%) (Figure 3A) and MELD score (when available, n=54) improved in 22 cases (40.7%) and worsened in 19 cases (35.2%) (Figure 3B). Based on Child score, liver disease progression (between D0 and end of treatment) was observed in 5 patients. One patient presented virological relapse. One patient was treated with PEG.

In parallel, mild ascites reversal was observed in 6/7 patients and refractory ascites reversal was observed in 5/7 patients. Two patients developed refractory ascites during treatment and 2 patients developed mild ascites. From the 14 patients with ascites at initiation of antiviral treatment, one had virological failure.

During antiviral treatment and follow-up, 3 patients were re-transplanted (at week 16 (n=1), between week 4 and week 24 post-treatment (n=2)) and 4 patients died (at week 1 (n=1), between week 4 and week 12 post-treatment (n=2), after week 24 post-treatment (n=1)). Causes of death were sepsis (n=2) or liver failure (n=2). All the 4 patients who died were cirrhotic; the 3 patients who died after treatment had virological failure; treatment regimens were SOF+RBV (n=3) or SOF+DCV+RBV (n=1). Deaths were considered unrelated to antiviral treatment in all cases; 3/4 occurred after end of treatment (5, 12 and 25 weeks). Re-transplantation was performed because of liver failure (week 16, n=1), chronic rejection (FU week 16, n=1), or de novo HCC (FU week 7, n=1). One patient presented virological relapse.

Safety

Thirty-two patients (25.6%) experienced at least one serious adverse event (Table 6). Infection was the most common serious adverse event (8.0%). Anemia was more frequent and more severe in patients who received RBV but was not related to fibrosis stage (Table 7).

Dosing of immunosuppressive drugs

Modifications in the dose of calcineurin and mTOR inhibitors, or MMF during antiviral treatment were performed at investigator's discretion. Dose changes during antiviral treatment were required in 25 patients (34.7%) on tacrolimus, 14 (36.8%) patients on cyclosporine, 6 (50.0%) patients on everolimus, and 7 (9.7%) patients on MMF. Only minimal dose modifications were required, on average of +10.7% for tacrolimus, -3.7% for cyclosporine, -1.7% for everolimus and +0.1% for MMF between baseline and end of treatment. Regarding the main antiviral treatment regimens used, dose changes of tacrolimus or cyclosporine were more frequent in patients treated with SOF+DCV+RBV (51.7%) when compared to patients treated with SOF+DCV (34.0%) or SOF+RBV (18.8%).

No significant over or under-dosage was observed, and one patient had graft rejection during antiviral therapy.

Discussion

Treatment of HCV recurrence after LT is a major goal and results have been impaired for a long time because of poor efficacy and high toxicity of PEG/RBV, even in combination with first generation protease inhibitors (7, 8). To our knowledge, the present study is one of the largest series of patients with recurrent hepatitis C and severe fibrosis (n=125), treated with SOF-based antiviral therapy.

After LT, recurrent hepatitis C begins with a first phase of acute hepatitis and can have thereafter two distinct clinical and histological patterns. The first one is the most frequent and the same than described in non-transplanted patients, characterized by a progression from chronic hepatitis to cirrhosis. The second type of recurrent hepatitis C after LT is specific for immunosuppressed patients and has been described as fibrosing cholestatic hepatitis (FCH). FCH leads to an inexorable deterioration of liver function (9, 10), and is associated with a high probability of death (> 50%) (11). We recently reported, from 23 patients included in the CUPILT cohort and presenting FCH, that SOF-based antiviral therapy could be highly effective, since all patients survived, without retransplantation, and 22 patients (96%) achieved a SVR12 (12). The present study focused on patients with severe fibrosis (METAVIR F3 and F4), outside the field of FCH, and confirms these promising results in a different population with severe hepatitis C recurrence. Indeed, in addition to fibrosis progression, natural history of recurrent HCV cirrhosis is also accelerated after LT. The probability of liver decompensation is > 40% at 1 year and >70% at 3 years in LT recipients vs. <5% and <10%, respectively, in immuno-competent patients (13, Berenguer, 2000 #1195, 14-16). The rate of progression from liver decompensation to death is also accelerated, with a 3-year survival of <10% following the first decompensation vs. >60% in immuno-competent patients (13, Berenguer, 2000 #1195, 15, 16). This explains that long-term graft and patient survival is significantly reduced in patients undergoing LT for HCV-related liver disease as compared to other indications (3). Therefore, viral eradication in patients with severe fibrosis is a major goal, in order to avoid death, or re-transplantation. The main result of our study is the high rate of SVR12, observed in a difficult-to-treat population (92.8%). These results look better than that initially reported by Charlton *et al.* (17) and Forns *et al.* (18),

from the first series using SOF after LT, in which only 70% and 59% of SVR12 were achieved, respectively. This was probably due to a non-optimal antiviral regimen used (SOF/RBV in all patients), as confirmed in our cohort in the subgroup of patients who received the SOF/RBV combination (68.4% of SVR rate). More recently, Pungpapong *et al.* reported the results from a multicenter study including 123 patients (all genotype 1, 30% METAVIR F3-F4) treated with a combination of SOF and SMV with or without RBV for 12 weeks ; a SVR12 was achieved in 90% of patients (19). These results were confirmed in the TARGET cohort, from 151 patients (all genotype 1) treated with SOF/SMV \pm RBV, for 12 weeks for most patients; a SVR12 was achieved in 88% of patients (20). Similarly, Gutierrez *et al.* reported a 93.4% rate of SVR12 in a cohort of 61 genotype 1 HCV patients (37.7% METAVIR F3-F4), treated with a combination of SOF and SMV for 12 weeks; interestingly, in METAVIR F3 and F4 patients infected with HCV genotype 1a, SVR12 was only 67% (21). Kwo *et al.* reported a 97% SVR12 rate in a small cohort of 34 LT recipients treated with the combination of ombitasvir/paritaprevir/dasabuvir \pm RBV, but only patients with no fibrosis or mild fibrosis were included (22). Finally, our good virological results are probably related to the frequent use in our series of a combination of SOF and DCV (73.6% of the patients); this is probably due to the pangenotypic effect of this combination and is in accordance with the excellent results of the phase 2 study evaluating this combination in non-transplanted patients (23).

An open and extremely relevant question is that of the potential clinical improvement after HCV eradication. We reported a dramatic improvement of liver function in our previous series of LT patients presenting FCH (12). In the present cohort, we observed in a majority of our cirrhotic patients, an improvement of liver function, based on Child score, during antiviral therapy. This was not the same when regarding MELD score but this was due to the worsening of renal function (and not liver function), in a cohort of “old” LT patients (8 years) with previous renal impairment. This observation is consistent with the results from Charlton *et al.* (24). In a phase 2 study, the efficacy of a combination SOF/LDV/RBV was evaluated from 337 patients infected with HCV genotypes 1 or 4, including a majority of cirrhotic patients, with mild, moderate, or severe hepatic impairment (including LT patients).

The vast majority of patients with Child–Pugh class B and C disease who had or not undergone LT, had improved MELD and Child scores at post-treatment week4 compared with baseline. Similarly, on the cohort of Forns *et al.*, clinical status of compensated and decompensated LT cirrhotic patients receiving SOF/RBV improved in 45% of the cases (18). Nevertheless, evolution of renal function during and after antiviral therapy is of great concern. We observed that worsening of MELD score was less frequent when evaluated at follow-up week 12 (vs. EOT), strongly suggesting that impaired renal function observed during antiviral treatment, partially resolved after the end of treatment. This needs to be more extensively evaluated from larger cohort.

Safety was carefully investigated in our study population with severe fibrosis and multiple co-medications. In our cohort, SAE were not very frequent (25.6% of the patients). The most frequent SAE was bacterial infection, with favorable outcome (no patient's death during antiviral treatment). Anemia was a frequent adverse event, observed in both patients with or without RBV, leading to RBV dose reduction or early interruption, EPO administration and even blood transfusions. As expected, anemia was more frequent and severe in patients treated with RBV, and this arises with the major issue of the optimal use of RBV (and dosage) in order to provide a significant benefit regarding antiviral efficacy. In the study by Charlton *et al.* (17) evaluating the SOF/RBV combination the initial dose of ribavirin was 400 mg followed by an escalation dose protocol based on hemoglobin levels. Despite this protocol, still one quarter of patient required RBV dose reduction and 33% had severe anemia. Thus, avoiding RBV from antiviral therapy would undoubtedly increase safety. Interestingly, it has been suggested that RBV could not add any benefit in non-cirrhotic patients treated by SOF/DCV irrespective to genotype and prior treatment exposition (23). Nevertheless, extrapolation of these results to LT patients, especially with severe fibrosis, needs further evaluation. Last but not least, SOF, DCV, SMV and LDV are not supposed to have significant drug-drug interactions with calcineurin inhibitors and mTOR inhibitors (25). Close monitoring of calcineurin inhibitors and mTOR inhibitors concentrations performed in our study confirmed that only mild changes of dosages were required during the antiviral treatment period.

Our study had several limitations. The first one is sample size that was not sufficient to allow precise evaluation of sub-groups according to fibrosis stage, HCV genotype or antiviral treatment regimen. Nevertheless, our results do not support a strong impact of fibrosis stage (F3 vs. F4). We acknowledge that the liver stiffness cut-offs chosen for the diagnosis of F3 and F4 fibrosis stages have been validated in HCV-infection outside the LT setting (6). In their systematic review on the diagnostic performance of transient elastography in HCV-recurrence after LT, Cholangitas *et al.* found variable cut-offs, ranging from 7.9 to 10.1 kPa and from 10.5 to 26.5 kPa for the diagnosis of F3 and F4, respectively (26). Given these data, we assumed that the use of the well validated cut-offs, falling in the same range than that described in LT, were the most appropriate as a non-invasive estimate of fibrosis in our study population. The second limitation is that it is a cohort study with heterogeneous treatment regimens, which was not designed to determine the optimal antiviral regimen (drugs and duration). Nevertheless, combination of SOF and DCV, with or without RBV, for 24 weeks was the main regimen used in our population and could therefore be considered as the standard option, regarding its pangenotypic activity, when available. In addition, since 6 out of our 7 patients who experienced virological failure were treated with SOF/RBV, this regimen should be used strictly for genotype 2 HCV only. Finally, due to relatively short follow-up we have been unable to provide clinical and histological outcome after HCV eradication; long-term data on survival (graft and patient) and reversion of fibrosis will be of great interest.

In conclusion, our study shows that SOF-based regimens allow achievement of SVR in the vast majority of patients presenting HCV recurrence with severe fibrosis following LT. These promising results are likely to dramatically change the prognosis in this difficult-to-treat population, with expected guarded long-term prognosis.

References

1. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. *Liver Transpl* 2003;9:1231-43.
2. Merion RM. Current status and future of liver transplantation. *Semin Liver Dis* 2010;30:411-21.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 2002;122:889-96.
4. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. *Gastroenterology* 1999;117:619-25.
5. Gane EJ. The natural history of recurrent hepatitis C and what influences this. *Liver Transpl* 2008;14 Suppl 2:S36-44.
6. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005;41:48-54.
7. Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebah M, Coilly A, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. *AIDS* 2015;29:53-8.
8. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. *J Hepatol* 2014;60:78-86.
9. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. *Hepatology* 1991;13:150-7.
10. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Legendre C, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. *Transplantation* 1997;63:158-60.
11. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. *Liver Transpl* 2010;16:1228-35.
12. Leroy V, Dumortier J, Coilly A, Sebah M, Fougerou-Leurent C, Radenne S, et al. Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing Cholestatic Hepatitis C After Liver Transplantation. *Clin Gastroenterol Hepatol* 2015.
13. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997;112:463-72.
14. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. *Liver Transpl* 2001;7:811-5.
15. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. *Hepatology* 2000;32:852-8.

16. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. *J Hepatol* 2000;32:673-84.
17. Charlton M, Gane E, Manns MP, Brown RS, Jr., Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. *Gastroenterology* 2015;148:108-17.
18. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. *Hepatology* 2014.
19. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. *Hepatology* 2015;61:1880-6.
20. Brown RS, Jr., O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Jr., et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. *Liver Transpl* 2016;22:24-33.
21. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. *Liver Transpl* 2015;21:823-30.
22. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Jr., et al. An interferon-free antiviral regimen for HCV after liver transplantation. *N Engl J Med* 2014;371:2375-82.
23. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med* 2014;370:211-21.
24. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. *Gastroenterology* 2015.
25. Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, et al. Drug interactions with new hepatitis C oral drugs. *Expert Opin Drug Metab Toxicol* 2015;11:333-41.
26. Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. *Transpl Int* 2010;23:861-70.

Figure legends**Figure 1:**

Viral kinetics according to fibrosis stage (F3/F4). No statistically significant difference was observed between the two groups.

Figure 2:

SVR12 rates according to treatment regimen, genotype, duration of treatment and previous HCV therapy post-LT.

Figure 3:

Evolution of CHILD (A, n=45) and MELD (B, n=54) available scores from initiation of treatment and follow-up week12 (F4 group, patient by patient).

Table 1: Baseline demographics and disease characteristics

	Global (n=125)	F3 (n=50)	F4 (n=75)
Gender (male)	98 (78.4%)	39 (78.0%)	59 (78.7%)
Age (years)	59.4 ± 9.0	59.5 ± 8.5	59.3 ± 9.4
Body mass index (kg/m ²)	24.4 ± 4.0 ¹⁹	24.2 ± 4.0 ⁹	24.6 ± 4.1 ¹⁰
HIV co-infection	4 (3.2%)	3 (6.0%)	1 (1.3%)
Indication for LT			
Cirrhosis	52 (41.6%)	16 (32.0%)	36 (48.0%)
HCC	65 (52.0%)	29 (58.0%)	36 (48.0%)
HCV ReLT	7 (5.6%)	5 (10.0%)	2 (2.7%)
Other	1 (0.8%)	0 (0.0%)	1 (1.3%)
Delay after LT (months)	95.9 ± 69.6	82.4 ± 71.4	104.9 ± 67.3
Immunosuppressive drugs			
Cyclosporine	38 (30.4%)	20 (40.0%)	18 (24.0%)
Tacrolimus	70 (56.0%)	22 (44.0%)	48 (64.0%)
Sirolimus	1 (0.8%)	1 (2.0%)	0 (0.0%)
Everolimus	11 (8.8%)	7 (14.0%)	4 (5.3%)
MMF	71 (56.8%)	30 (60.0%)	41 (54.7%)
Previous therapy post-LT			
Treatment-naïve	45 (36.0%)	23 (46.0%)	22 (29.3%)
RBV	2 (1.6%)	0 (0.0%)	2 (2.7%)
PEG+RBV	57 (45.6%)	19 (38.0%)	38 (50.7%)
PEG+RBV+BOC	5 (4.0%)	2 (4.0%)	3 (4.0%)
PEG+RBV+TLV	14 (11.2%)	5 (10.0%)	9 (12.0%)
RBV+SOF	2 (1.6%)	1 (2.0%)	1 (1.3%)
Previous course of HCV Therapy post-LT	1		1
Treatment-naïve	45 (36.3%)	23 (46.0%)	22 (29.7%)
Breakthrough	9 (7.3%)	5 (10.0%)	4 (5.4%)
Relapse	14 (11.3%)	7 (14.0%)	7 (9.5%)
Non-responders	30 (24.2%)	9 (18.0%)	21 (28.4%)
Intolerance	26 (21.0%)	6 (12.0%)	20 (27.0%)
HCV Genotype	1	1	
1	97 (78.2%)	36 (73.5%)	61 (81.3%)
2	1 (0.8%)	0 (0%)	1 (1.3%)
3	14 (11.3%)	7 (14.3%)	7 (9.3%)
4	11 (8.9%)	5 (10.2%)	6 (8.0%)
5	1 (0.8%)	1 (2.0%)	0 (0%)
HCV Viral load (log ₁₀ IU/mL)	6.1 ± 1.0	6.3 ± 0.6	6.0 ± 1.2
Baseline CHILD score	6.4 ± 1.3 ¹²	-	6.4 ± 1.3 ¹²
Baseline CHILD class	¹²		¹²
Class A (5-6 points)	39 (61.9%)	-	39 (61.9%)

Class B (7-9 points)	23 (36.5%)	-	23 (36.5%)
Class C (10-15 points)	1 (1.6%)	-	1 (1.6%)
Baseline MELD	11.8 ± 4.1 ³	-	11.8 ± 4.1 ³
Baseline MELD class	³		³
[6-10[26 (36.1%)	-	26 (36.1%)
[10-15[27 (37.5%)	-	27 (37.5%)
[15-20[16 (22.2%)	-	16 (22.2%)
[20-25[3 (4.2%)	-	3 (4.2%)
Ascites	⁵	³	²
No ascites	106 (88.3%)	47 (100%)	59 (80.8%)
Mild to moderate	7 (5.8%)	0 (0.0%)	7 (9.6%)
Refractory	7 (5.8%)	0 (0.0%)	7 (9.6%)
Hepatic encephalopathy	⁴	³	¹
No	121 (100%)	47 (100%)	74 (100%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
AST (IU/L)	91.6 ± 70.9 ¹	82.8 ± 59.0 ¹	97.4 ± 77.6
ALT (IU/L)	81.2 ± 53.4 ¹	84.7 ± 54.1 ¹	79.0 ± 53.2
γGT(IU/L)	278.3 ± 295.1 ¹	285.3 ± 300.0 ¹	273.7 ± 293.8
ALP (IU/L)	153.0 ± 103.3 ¹²	147.5 ± 90.2 ⁶	156.6 ± 111.3 ⁶
Total bilirubin (μmol/L)	20.9 ± 16.9 ⁴	16.5 ± 12.5 ²	23.7 ± 18.8 ²
Creatinine (μmol/L)	116.5 ± 62.8	123.2 ± 69.4	112.0 ± 58.0
eGFR MDRD (mL/min)	67.5 ± 26.6	63.6 ± 24.5	70.2 ± 27.9
Albumin (g/L)	36.3 ± 6.0 ¹⁴	37.6 ± 6.0 ⁶	35.5 ± 5.9 ⁸
Hemoglobin (g/dL)	12.9 ± 1.9	13.1 ± 1.9	12.8 ± 1.9
Platelet count (G/L)	119.5 ± 67.4	128.9 ± 60.8	113.2 ± 71.2
Leukocytes (G/L)	4.3 ± 1.7	4.5 ± 1.5	4.2 ± 1.7
Neutrophil count (G/L)	2.7 ± 1.2 ³	2.8 ± 1.2 ¹	2.6 ± 1.3 ²
INR	1.2 ± 0.3 ⁷	1.2 ± 0.3 ⁵	1.2 ± 0.3 ²
Prothrombin Ratio (%)	82.4 ± 19.9 ⁵	88.1 ± 19.6 ²	78.5 ± 19.3 ³

Quantitative results are expressed as mean ± SD.

ⁿ number of missing data

Table 2: Antiviral therapy regimens

Regimen	Global	Expected duration	
		12 weeks	24 weeks
	125	18	107
SOF+DCV	59 (47.2%)	12 (66.7%)	47 (43.9%)
SOF+DCV+RBV	32 (25.6%)	1 (5.6%)	31 (29.0%)
SOF+RBV	19 (15.2%)	0 (0.0%)	19 (17.8%)
SOF+PEG+RBV	5 (4.0%)	2 (11.1%)	3 (2.8%)
SOF+LDV+RBV	4 (3.2%)	1 (5.6%)	3 (2.8%)
SOF+SMV	5 (4.0%)	2 (11.1%)	3 (2.8%)
SOF/SMV+SOF/DCV*	1 (0.8%)	0 (0.0%)	1 (0.9%)

* One patient was switched from SOF/SMV to SOF/DCV because of slow virological response

Accepted Article

Table 3: Virological response during and after treatment (intent-to-treat analysis)

Variable(s)	Global (n=125)	Stage F3 (n=50)	Stage F4 (n=75)
W0*			
HCV RNA < LLOQ	2 (1.6%)	0 (0.0%)	2 (2.7%)
W4			
HCV RNA < LLOQ	58 (46.4%)	26 (52.0%)	32 (42.7%)
Causes of treatment failure	death (n=1), non response (n=64), missing data (n=2)	non response (n=23), missing data (n=1)	death (n=1), non response (n=41), missing data (n=1)
W8			
HCV RNA < LLOQ	106 (84.8%)	45 (90.0%)	61 (81.3%)
Causes of treatment failure	death (n=1), non response (n=16), missing data (n=2)	non response (n=5)	death (n=1), non response (n=11), missing data (n=2)
W12			
HCV RNA < LLOQ	119 (95.2%)	48 (96.0%)	71 (94.7%)
Causes of treatment failure	death (n=1), non response (n=5)	non response (n=2)	death (n=1), non response (n=3)
EOT			
HCV RNA < LLOQ	121 (96.8%)	49 (98.0%)	72 (96.0%)
Causes of treatment failure	death (n=1), virological breakthrough (n=1), missing data (n=2)	virological breakthrough (n=1)	death (n=1), missing data (n=2)
FUW4			
HCV RNA < LLOQ	115 (92.0%)	47 (94.0%)	68 (90.7%)
Causes of treatment failure	death (n=1), virological breakthrough (n=1), virological relapse (n=6), lost to follow-up (n=1), missing data (n=1)	virological breakthrough (n=1), virological relapse (n=1), lost to follow-up (n=1)	death (n=1), virological relapse (n=5), missing data (n=1)
FUW12			
HCV RNA < LLOQ	116 (92.8%)	47 (94.0%)	69 (92.0%)
Causes of treatment failure	death (n=1), virological breakthrough (n=1), virological relapse (n=6), lost to follow-up (n=1)	virological breakthrough (n=1), virological relapse (n=1), lost to follow-up (n=1)	death (n=1), virological relapse (n=5)

*2 patients had undetectable HCV RNA at initiation of SOF (lead-in phase with PEG/RBV)

Table 4: Characteristics of patients with treatment failure

Patient	Antiviral treatment failure	Antiviral treatment regimen	Antiviral treatment duration	Outcome	Genotype	Fibrosis stage
1	Relapse FUweek4	SOF/DCV	24 weeks	Alive	4	F4
2	Relapse FUweek4	SOF/RBV	24 weeks	Died*	1b	F4
3	Relapse FUweek4	SOF/RBV	24 weeks	Died*	4	F4
4	Breakthrough	SOF/RBV	28 weeks	Alive	1b	F3
5	Relapse FUweek4	SOF/RBV	24 weeks	Alive	1a	F3
6	Relapse FUweek4	SOF/RBV	24 weeks	Died*	1	F4
7	Relapse FUweek12	SOF/RBV	24 weeks	Alive – Re-transplantation	3a	F4

* One patient died before FUW12, two patients died after FUW12

Table 5: Outcome of clinical features and laboratory tests during antiviral treatment

Variable(s)*	J0 (n=125)	EOT (n=124)	<i>p</i> J0 vs EOT
BMI	106 24.4 ± 4.0 (16.3 ; 21.6 ; 24.2 ; 27.2 ; 35.9)	89 25.1 ± 4.6 (15 ; 22 ; 24.2 ; 28.2 ; 40.1)	<i>p</i> = .04
AST (IU/L)	124 91.6 ± 70.9 (21.0 ; 45.5 ; 74.0 ; 109.5 ; 548.0)	118 31.1 ± 14.4 (0.7 ; 22.0 ; 28.0 ; 38.0 ; 111.0)	<i>p</i> < .001
ALT (IU/L)	124 81.2 ± 53.4 (12.0 ; 36.0 ; 72.0 ; 111.5 ; 279.0)	118 26.0 ± 13.3 (0.5 ; 16.0 ; 23.0 ; 33.0 ; 67.0)	<i>p</i> < .001
GGT (IU/L)	124 278.3 ± 295.1 (16.0 ; 66.5 ; 153.5 ; 342.5 ; 1537.0)	116 99.9 ± 122.8 (14.0 ; 34.0 ; 53.5 ; 105.0 ; 727.0)	<i>p</i> < .001
AP (IU/L)	113 153.0 ± 103.3 (52.0 ; 99.0 ; 128.0 ; 171.0 ; 847.0)	109 114.9 ± 72.4 (47.0 ; 79.0 ; 96.0 ; 134.0 ; 665.0)	<i>p</i> < .001
Bilirubin (total) (µmol/L)	121 20.9 ± 16.9 (5.0 ; 10.0 ; 16.0 ; 24.0 ; 116.3)	117 22.7 ± 74.2 (3.0 ; 8.4 ; 13.0 ; 19.0 ; 809.0)	<i>p</i> = .80
Creatinine (µmol/L)	125 116.5 ± 62.8 (48.0 ; 81.0 ; 102.0 ; 128.0 ; 486.0)	121 128.3 ± 90.4 (52.0 ; 88.0 ; 106.0 ; 142.0 ; 849.0)	<i>p</i> = .002
eGFR MDRD (mL/min)	125 67.5 ± 26.6 (8.8 ; 48.2 ; 64.7 ; 86.3 ; 170.3)	121 62.9 ± 24.3 (6.0 ; 45.5 ; 63.3 ; 76.2 ; 124.4)	<i>p</i> < .001
Albumin (g/L)	111 36.3 ± 6 (21.0 ; 32.0 ; 36.4 ; 40.5 ; 56.0)	108 38.4 ± 5.4 (21.6 ; 35.3 ; 39.0 ; 42.1 ; 48.0)	<i>p</i> < .001
Platelets (G/L)	125 119.5 ± 67.4 (19.0 ; 69.0 ; 111.0 ; 163.0 ; 389.0)	120 133.8 ± 66.6 (27.0 ; 81.0 ; 128.0 ; 170.5 ; 343.0)	<i>p</i> < .001
INR	118 1.2 ± 0.3 (0.9 ; 1.0 ; 1.1 ; 1.2 ; 2.4)	113 1.2 ± 0.3 (0.9 ; 1.0 ; 1.1 ; 1.3 ; 2.7)	<i>p</i> = .96

Quantitative results are expressed as mean ± SD (range;IQR;median)

ⁿ: number of missing data.

Table 6: Safety profile of antiviral therapy regimens

	Global (n=125)	F3 (n=50)	F4 (n=75)
SAE ^a	32 (25.6%)	10 (20.0%)	22 (29.3%)
Infection	10 (8.0%)	2 (4.0%)	8 (10.7%)
Anemia	8 (6.4%)	2 (4.0%)	6 (8.0%)
Renal failure	5 (4.0%)	1 (2.0%)	4 (5.3%)
Neutropenia	3 (2.4%)	1 (2.0%)	2 (2.7%)
Cardiac Disorder	3 (2.4%)	1 (2.0%)	2 (2.7%)
Leukopenia	2 (1.6%)	1 (2.0%)	1 (1.3%)
Rejection	1 (0.8%)	1 (2.0%)	0 (0.0%)
Thrombocytopenia	1 (0.8%)	0 (0.0%)	1 (1.3%)
Hyperbilirubinemia	1 (0.8%)	0 (0.0%)	1 (1.3%)
Others	15 (12.0%)	5 (10.0%)	10 (13.3%)


^a A serious adverse event refers to any untoward medical occurrence or effect that at any dose:

- results in death,
- is life-threatening,
- results in persistent or significant disability or incapacity,
- requires hospitalization or prolongation of existing hospitalization,
- is a congenital anomaly or birth defect,
- is a grade 4 clinical adverse event,
- is a grade 4 biological adverse event,
- is an "important medical event" (medical events, based upon appropriate medical judgment, which may jeopardize the subject or may require medical or surgical intervention to prevent one of the above characteristics/consequences).

Table 7: Anemia during antiviral therapy (according to RBV use and fibrosis stage)


Anemia				p
	Global (n=125)	RBV+ (n=60)	RBV- (n=65)	
Grade 0 (>10 g/dl with Trt)	5 (4.0%)	4 (6.7%)	1 (1.5%)	p = .03
Grade 1/2 (<10 g/dl)	26 (20.8%)	15 (25.0%)	11 (16.9%)	
Grade 3/4 (<8 g/dl)	14 (11.2%)	10 (16.7%)	4 (6.2%)	
Erythropoietin use	34 (27.2%)	22 (36.7%)	12 (18.5%)	p = .02
Blood transfusion	10 (8.0%)	8 (13.3%)	2 (3.1%)	p = .048
RBV dose reduction for AE	21 (16.8%)	21 (35.0%)	0 (0.0%)	NA
Discontinuation of RBV	4 (3.2%)	4 (6.7%)	0 (0.0%)	NA
Maximum hemoglobin decrease (g/dL)	-1.8 ± 1.8	-2.9 ± 1.7	-0.9 ± 1.3	p < .001
	Global (n=125)	F3 (n=50)	F4 (n=75)	
Grade 0 (>10 g/dl with Trt) :	5 (4.0%)	2 (4.0%)	3 (4.0%)	p = .79
Grade 1/2 (<10 g/dl)	26 (20.8%)	12 (24.0%)	14 (18.7%)	
Grade 3/4 (<8 g/dl)	14 (11.2%)	4 (8.0%)	10 (13.3%)	
Erythropoietin use	34 (27.2%)	13 (26.0%)	21 (28.0%)	p = .81
Blood transfusion	10 (8.0%)	3 (6.0%)	7 (9.3%)	p = .74
RBV dose reduction for AE	21 (16.8%)	8 (16.0%)	13 (17.3%)	p = .85
Discontinuation of RBV	4 (3.2%)	0 (0.0%)	4 (5.3%)	p = .15
Maximum hemoglobin decrease (g/dL)	-1.8 ± 1.8	-1.9 ± 1.7	-1.8 ± 1.8	p = .89

Quantitative results are expressed as mean ± SD



105x58mm (300 x 300 DPI)

Accepted



107x61mm (300 x 300 DPI)

Accepted




Figure 3A
105x58mm (300 x 300 DPI)

Accepted




Figure 3B
105x58mm (300 x 300 DPI)

Accepted